Lilly, Pfizer to work with Joslin on kidney failure treatments

Joslin Diabetes Center said its new Office of Commercialization and Ventures will collaborate with drug giants Eli Lilly and Co. and Pfizer Inc. to accelerate research aimed at predicting kidney failure and developing treatments for it.

The Joslin Office of Commercialization and Ventures was created in 2011 to work closely with the pharmaceutical industry to do research and develop drugs for the diabetes community. The Lilly-Pfizer collaboration is the first time two pharmaceutical companies have joined forces with Joslin, Joslin said.


As part of this cofunded research effort, Joslin said it will analyze samples from a unique biorepository collected and studied by Dr. Andrzej Krolewski, who heads Joslin’s Section on Genetics and Epidemiology.

One goal of the effort is to identify biomarkers for predicting kidney disease. Renal complications, also known as diabetic nephropathy, are one of the most life-threatening complications of diabetes, Joslin said in its press release.

Chris Reidy can be reached at
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of